339 related articles for article (PubMed ID: 18046235)
1. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
[TBL] [Abstract][Full Text] [Related]
4. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.
Furrer E; Berdugo M; Stella C; Behar-Cohen F; Gurny R; Feige U; Lichtlen P; Urech DM
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):771-8. PubMed ID: 18757508
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intravitreal bevacizumab (Avastin).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Singh RJ
Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
[TBL] [Abstract][Full Text] [Related]
8. Predicted biological activity of intravitreal VEGF Trap.
Stewart MW; Rosenfeld PJ
Br J Ophthalmol; 2008 May; 92(5):667-8. PubMed ID: 18356264
[TBL] [Abstract][Full Text] [Related]
9. Monitoring ocular drug therapy by analysis of aqueous samples.
Campochiaro PA; Choy DF; Do DV; Hafiz G; Shah SM; Nguyen QD; Rubio R; Arron JR
Ophthalmology; 2009 Nov; 116(11):2158-64. PubMed ID: 19700195
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
Lowe J; Araujo J; Yang J; Reich M; Oldendorp A; Shiu V; Quarmby V; Lowman H; Lien S; Gaudreault J; Maia M
Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704
[TBL] [Abstract][Full Text] [Related]
11. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
Michels S; Rosenfeld PJ
Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
[TBL] [Abstract][Full Text] [Related]
13. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
Krohne TU; Eter N; Holz FG; Meyer CH
Am J Ophthalmol; 2008 Oct; 146(4):508-12. PubMed ID: 18635152
[TBL] [Abstract][Full Text] [Related]
14. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.
Ottiger M; Thiel MA; Feige U; Lichtlen P; Urech DM
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):779-86. PubMed ID: 18757511
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
[TBL] [Abstract][Full Text] [Related]
16. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.
Park SJ; Oh J; Kim YK; Park JH; Park JY; Hong HK; Park KH; Lee JE; Kim HM; Chung JY; Woo SJ
Eye (Lond); 2015 Apr; 29(4):561-8. PubMed ID: 25592118
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
Miyake T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ogasawara K; Ohji M
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
[TBL] [Abstract][Full Text] [Related]
18. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach.
Xu L; Lu T; Tuomi L; Jumbe N; Lu J; Eppler S; Kuebler P; Damico-Beyer LA; Joshi A
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):1616-24. PubMed ID: 23361508
[TBL] [Abstract][Full Text] [Related]
20. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes.
Ahn SJ; Ahn J; Park S; Kim H; Hwang DJ; Park JH; Park JY; Chung JY; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):567-73. PubMed ID: 24398088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
